Drug Trial Radar · NCT01586364
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
Last checked: Nov 20, 2026Latest source record: May 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
May 8, 2006
Primary completion
Nov 21, 2008
Study completion Dec 22, 2008
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- Collaborators
- QuatRx Pharmaceuticals
- First posted
- Apr 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.
Conditions
- Atrophy
- Vaginal Diseases
Interventions
Ospemifene 60Mg Oral TabletDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Week 13 (Phone Contact) to Week 56 (Visit 4)
- Change From Baseline in Serum Lipid Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Serum Lipid Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Blood Pressure at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Pulse Rate at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Weight at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Body Mass Index (BMI) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Blood Pressure at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Pulse Rate at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Weight at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in BMI at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Visual Evaluation of Vagina at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Visual Evaluation of Vagina at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Assessment of Cervical Pap Smear Samples (if Cervix is Intact)Time frame: Week 52 (Visit 3)
- Assessment of Breast Palpation at Visit 2Time frame: Week 26 (Visit 2)
- Assessment of Breast Palpation at Visit 3Time frame: Week 52 (Visit 3)
- Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Fibrinogen (Plasma) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Fibrinogen (Plasma) Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Erythrocyte Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Hemoglobin Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Hematocrit and Red Blood Cell (RBC) Distribution Width at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Erythrocyte Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Hemoglobin Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Hematocrit and RBC Distribution Width at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in MCV and MPV at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Albumin and Total Protein Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase (CK) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and Blood Urea Nitrogen (BUN) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Albumin and Total Protein Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in ALT, AST and CK Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and BUN Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in pH of Urine at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Specific Gravity of Urine at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in pH of Urine at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Specific Gravity of Urine at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Estradiol (E2) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in Testosterone Levels at Visit 2Time frame: Baseline to Week 26 (Visit 2)
- Change From Baseline in E2 Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in FSH and LH Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in SHBG Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
- Change From Baseline in Testosterone Levels at Visit 3Time frame: Baseline to Week 52 (Visit 3)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.